Abstract
The main aim of the present study was to evaluate Azithromycin and Chloroquine drug in combination therapy used in the treatment of Chloroquine resistant malaria by increasing the solubility and dissolution rate of Azithromycin and Chloroquine phosphate by complexation techniques using hydroxypropyl β-Cyclodextrins with varying concentrations and after selection of proper ratio with carriers an attempt was made to develop and evaluate fast dissolving tablet of Azithromycin Chloroquine phosphate using synthetic super disintegrates. The main objective of the present investigation is to explore the possibility of improving low solubility and hence dissolution profile of Azithromycin and Chloroquine phosphate with fewer side effects and reduce dosage regimen with less toxicity for treatment for many acute and chronic disease. Evaluation of solubility profile, the pre and post compression parameters of the tablets, drug content, % drug release formulation containing hydroxypropyl β-Cyclodextrins from Azithromycin FDT shows 71.25 to 86.0% at the end of 45 min and Chloroquine phosphate shows 76.33 to 86.4% drug release at the end of 45 min., drug content of all the formulations were with its range and the disintegration time 19-29 Sec. Hence HPβCD technology can open up new perspectives for both existing and future drugs as new dosage forms, new administration routes and new formulations become available.
